2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-158936
    Lumula 511229-72-4
    Lumula (Maxeyprost) is an ethyl amide derivative of Unoprostone (HY-106916).
    Lumula
  • HY-158978
    Multitarget AD inhibitor-2
    Multitarget AD inhibitor-2 (Compound VN-19) is a multitargeting inhibitor acetylcholinesterase (AChE, IC50=0.14 μM), butyrylcholinesterase (BChE, IC50=11.6 μM), monoamine oxidase B (MAO B, IC50=0.45 μM). Multitarget AD inhibitor-2 inhibits self-induced aggregation of amyloid beta protein Aβ1-42 (inhibition rate is 47.3% at 20 μM), and downregulates the level of ROS in SH-SY5Y (80 inhibition rate at 25 μM). Multitarget AD inhibitor-2 ameliorates the cognitive decline in Scopolamine (HY-N0296)-induced Alzheimer’s Disease zebrafish models.
    Multitarget AD inhibitor-2
  • HY-158979
    Nav1.8-IN-14 2417373-18-1
    Nav1.8-IN-14 (compound 20) is a potent and selective Nav1.8 inhibitor. Nav1.8-IN-14 can be used in the study of pain-related diseases.
    Nav1.8-IN-14
  • HY-159081
    AChE/BChE-IN-20
    AChE/BChE-IN-20 (compound 3m) is an acetylcholinesterase (AChE, IC50=34.81 µM) and butylcholinesterase (BChE, IC50=20.66 µM) inhibitor, which has been demonstrated to have affinity for key enzyme pockets and favorable interaction profiles by molecular docking and kinetic simulations, and can be used in the study of Alzheimer's disease.
    AChE/BChE-IN-20
  • HY-159088
    KOR agonist 2
    KOR agonist 2 (Compound 23p) is an agonist for κ opioid receptor (KOR) with Ki of 1.9 nM. KOR agonist 2 exhibits analgesic effect in mouse models with ED50 of 1.30 mg/kg. KOR agonist 2 exhibits high clearance rate (2 mg/kg, i.v.) in mice, high metabolism and clearance in liver microsomes.
    KOR agonist 2
  • HY-159094
    Nav1.8-IN-15 524061-69-6
    Nav1.8-IN-15 (compound 6) is a potent Nav1.8 inhibitor. Nav1.8-IN-15 shows analgesic effect. Nav1.8-IN-15 has the potential for the research of chronic pain.
    Nav1.8-IN-15
  • HY-159106
    MeSeI 2901664-87-5
    MeSeI exhibits a weak inhibitory activity against monoamine oxidase MAO-A and MAO-B (IC50=198.8 µM). MeSeI regulates dopamine receptor D2 and norepinephrine receptor α2, β1, and exhibits antidepressant-like effect in mice. MeSeI is orally active.
    MeSeI
  • HY-159113
    PCC0105003
    PCC0105003 is a potent MARK inhibitor. PCC0105003 can be used in the study of neuropathic pain.
    PCC0105003
  • HY-159116
    AChE-IN-69 2755986-33-3
    AChE-IN-69 (compound 7o) is a potent AChE inhibitor with an IC50 value of 1.67 µM. AChE-IN-69 has the potential for the research of Alzheimer’s disease.
    AChE-IN-69
  • HY-159121
    sEH inhibitor-17 2823295-37-8
    sEH inhibitor-17 (compound 4f) is an oral active soluble epoxide hydrolase (sEH) inhibitor with the IC50 of 2.94 nM. sEH inhibitor-17 shows anti-inflammatory efficacy.
    sEH inhibitor-17
  • HY-159133
    BuChE-IN-13
    BuChE-IN-13 (compound 3) is a BuChE inhibitor and shows anti-Alzheimer activity. BuChE-IN-13 can be used for study of neurodegenerative disease.
    BuChE-IN-13
  • HY-159143
    BChE-IN-33
    BChE-IN-33 (compound 4r), an arylaminonaphthol derivative, is a potent butyrylcholinesterase (BChE) inhibitor with an IC50 of 14.78 µM. BChE-IN-33 also inhibits CYP2C19, CYP2C9, CYP2D6. BChE-IN-33 shows potent antioxidant activity with IC50 values of 150.48 μM, 2.56 μM and 4.61 μM by DPPH, ABTS, Ferric-phenanthroline assay, respectively. BChE-IN-33 has the potential for Alzheimer research.
    BChE-IN-33
  • HY-159146
    PPARα agonist 4
    PPARα agonist 4 (compound BH400) is a PPARα agonist (EC50= 1.2 μM). PPARα agonist 4 also inhibits STING (IC50: 8.1 μM). PPARα agonist 4 reduces the CoCl2-induced production of ROS and LPS-induced secretion of IL-6. The PPARα agonist 4 restores the decreased expression of PCG1α induced by LPS.
    PPARα agonist 4
  • HY-159151
    AChE/Aβ-IN-6
    BACE1-IN-15 (compound 4j) is a potent inhibitor of BACE1 (β-secretase) that can inhibited the copper ion induced Aβ toxicity, with the EC50 of 0.68 μM.
    AChE/Aβ-IN-6
  • HY-159152
    PQM-164 2226535-25-5
    PQM-164 (Compound 3e) has antioxidant activity (IC50: 0.93 μM for DPPH radical). PQM-164 shows anti-inflammatory activity against 6-OHDA (HY-B1081A)-induced neuronal damage in activated microglial cells. PQM-164 decreases the accumulation of α-synuclein. PQM-164 promotes nuclear translocation of Nrf2 and its transcriptional activity. PQM-164 can be used for research of Parkinson’s disease.
    PQM-164
  • HY-159171
    sEH/HDAC6-IN-2 3009011-58-6
    sEH/HDAC6-IN-2 is a potent dual soluble epoxide hydrolase (sEH) and HDAC6 inhibitor with IC50s of 0.9 nM, 46.8 nM, and 8 nM for human sEH, mouse sEH, and HDAC6, respectively. sEH/HDAC6-IN-2 can be used for the study of inflammatory pain.
    sEH/HDAC6-IN-2
  • HY-159173
    AChE-IN-71 1708114-58-2
    AChE-IN-71 (compound 12A) is a AChE inhibitor. AChE-IN-71 can be used in the study of Alzheimer’s disease.
    AChE-IN-71
  • HY-159177
    M4 mAChR Modulator-1
    M4 mAChR Modulator-1 (compound 23i) is a M4 mAChR positive allosteric modulator (PAM). M4 mAChR Modulator-1 exhibits significantly greater cooperativity with ACh in β-arrestin recruitment over G protein activation. M4 mAChR Modulator-1 displays weak PAM effect in G protein-mediated responses, but strong PAM effect in β-arrestin recruitment.
    M4 mAChR Modulator-1
  • HY-159482
    SBN-284
    SBN-284 (compound 3x) is a dual inhibitor of blood-brain permeable Cholinesterases and the NLRP3 inflammasome and is effective against EeAChE, hAChE and eqBChE, the IC50 values of are 0.37, 0.31, 0.29 μM respectively, and the EC50 of NLRP3 inflamm is 1 μM. SBN-284 can be used in Alzheimer's disease research.
    SBN-284
  • HY-159492
    5-HT7 receptor ligand 2
    5-HT7 receptor ligand 2 (compound 32) is an arylpiperazinehydrazine ligand for 5-HT7R (Ki=178 nM). 5-HT7 receptor ligand 2 has good membrane permeability, low hepatotoxicity and cardiotoxicity, and high plasma protein binding. 5-HT7 receptor ligand 2 shows neuroprotective effects in SH-SY5Y cells and can be used for the study of central nervous system related diseases.
    5-HT7 receptor ligand 2
Cat. No. Product Name / Synonyms Application Reactivity